OUR EXPERT NETWORK

• Reprogramming The Tumor Microenvironment: Why RNA Immunotherapy Is Targeting Liver Metastases (Pt. 1)

  RNA/DNA immunotherapy may overcome liver metastases by reprogramming innate immunity, restoring interferon signaling, and improving responses to checkpoint inhibitors.

• Beyond Protein Targets: Why The Regulatory Genome Could Redefine RNA Medicine (Pt. 1)

  Explore how the regulatory genome and lncRNAs are shifting RNA medicine beyond protein targets, enabling cell-state reprogramming to treat disease at its source.

• Beyond Better Models: Why The Future Of AI-Designed mRNA Depends On More Relevant Biological Data

  AI can optimize mRNA only if it's trained on biologically relevant data. Better therapeutic datasets — not just better algorithms — will drive the next generation of RNA medicines.

• The Delivery Challenge For In Vivo Cell Engineering

  As RNA therapies expand beyond the liver, delivery—not payload design—has become the defining challenge for precise, scalable in vivo cell engineering.

• Building An ASO For TUBB4A-Related Leukodystrophy (Pt. 1)

  SynaptixBio CEO Dan Williams explains how the company selected an ASO for TUBB4A leukodystrophy by balancing potency, safety, and translational rigor to advance a rare disease therapy.